SEC Comment Letter 0000000000-25-003548 to INTENSITY THERAPEUTICS, INC. (INTS)

INTENSITY THERAPEUTICS, INC.
Date: April 2, 2025 · CIK: 0001567264 · Accession: 0000000000-25-003548

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 2, 2025

Author

Division of

Form

UPLOAD

Company

INTENSITY THERAPEUTICS, INC.

Letter

Re: Intensity Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted March 28, 2025 CIK No. 0001567264 Dear Lewis H. Bender:

April 2, 2025

Lewis H. Bender President, Chief Executive Officer and Chairman Intensity Therapeutics, Inc. 1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ivan K. Blumenthal, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 2, 2025

Lewis H. Bender
President, Chief Executive Officer and Chairman
Intensity Therapeutics, Inc.
1 Enterprise Drive, Suite 430
Shelton, CT 06484-4779

 Re: Intensity Therapeutics, Inc.
 Draft Registration Statement on Form S-1
 Submitted March 28, 2025
 CIK No. 0001567264
Dear Lewis H. Bender:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Ivan K. Blumenthal, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io